Hepatocellular Carcinoma

Why trials studying Hepatocellular Carcinoma stopped, in this sample of ClinicalTrials.gov.

28 stopped trials with a clear reason; 89% ended for non-scientific reasons.

Trials

• SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
  NCT07274774 · SUSPENDED · slow accrual
  “Difficult to recruit patients”
• Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma
  NCT06405061 · SUSPENDED · other
  “Mid-term data analysis for the project has been completed; enrollment is now suspended.”
• Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization
  NCT07178093 · TERMINATED · slow accrual
  “poor accrual and insufficient drug supply”
• A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
  NCT05418387 · WITHDRAWN · logistics pi
  “The study will be withdrawn as the Principal Investigator, Ken Batai, left the institution prior to study activation.”
• Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
  NCT05359861 · TERMINATED · funding business
  “Sponsor decision”
• Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
  NCT05171166 · TERMINATED · slow accrual
  “Difficult to enroll participants”
• Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
  NCT05292443 · WITHDRAWN · slow accrual
  “No participants were enrolled”
• The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol
  NCT04178642 · WITHDRAWN · slow accrual
  “no participants enrolled”
• Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
  NCT04116320 · TERMINATED · slow accrual
  “Unable to enroll enough patients to complete targeted enrollment in a reasonable time.”
• Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC
  NCT03958669 · TERMINATED · logistics pi
  “Slow recruitment due to COVID-19 pandemic and several newly approved treatment options”
• Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
  NCT04234113 · TERMINATED · futility
  “Due to lack of efficacy shown at the time of the interim analysis.”
• Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
  NCT04106167 · TERMINATED · funding business
  “This study was terminated by the Sponsor.”
• Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
  NCT04268888 · SUSPENDED · slow accrual
  “Analysis meant the study should close to recruitment”
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
  NCT03829501 · TERMINATED · funding business
  “Early discontinuation based on strategic sponsor decision not driven by any safety concerns.”
• HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
  NCT03803254 · WITHDRAWN · slow accrual
  “No participants enrolled”
• Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
  NCT03219372 · TERMINATED · slow accrual
  “Study discontinued due to low accrual.”
• APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
  NCT03655613 · TERMINATED · logistics pi
  “Study terminated due to administrative reasons.”
• Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
  NCT02950025 · TERMINATED · slow accrual
  “Low accrual”
• LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma
  NCT02524119 · TERMINATED · funding business
  “This study was terminated after the sponsor withdrew our support”
• A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
  NCT02460991 · TERMINATED · slow accrual
  “Slow enrollment”
• 11C-acetate for Treatment Response After Radiotherapy for HCC
  NCT02549755 · TERMINATED · slow accrual
  “Poor enrollment”
• DEB-TACE for Hepatocellular Carcinoma
  NCT02748161 · TERMINATED · slow accrual
  “Low enrollment”
• Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma
  NCT02802124 · TERMINATED · slow accrual
  “For tumor locates away from GI the planned enrolled patient had been completed, but for tumor locates closely to GI only 6 patients had been enrolled because not many eligible patients were available.”
• Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma
  NCT01489410 · WITHDRAWN · logistics pi
  “Insufficient staff”
• Chemoembolization for Hepatocellular Carcinoma
  NCT02821533 · TERMINATED · slow accrual
  “Poor case accrual”
• ABT-888 and Temozolomide for Liver Cancer
  NCT01205828 · TERMINATED · futility
  “Lack of efficacy”
• Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)
  NCT00823290 · TERMINATED · logistics pi
  “Investigator left site”
• Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer
  NCT00151671 · TERMINATED · slow accrual
  “insufficient enrollment rate”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.